IceCure Medical Ltd.
IceCure Medical Ltd. is a medical device company incorporated in Israel with subsidiaries in the United States, Hong Kong, and China. It develops and commercializes minimally invasive cryoablation systems that use liquid nitrogen to freeze and destroy tumors in the human body as an alternative to surgical removal.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaLiquid nitrogen-based devices used to freeze and destroy tumors through minimally invasive procedures.
Disposable or procedure-related items and uses tied to installed cryoablation systems.
Installation, training, and clinical support for hospitals and physicians using ProSense®.
Tuotteet
Raportoitu · osuus liikevaihdosta- Disposables60,8 %
- Systems39,2 %
Lähde: 20-F FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
The company sells primarily to hospitals, clinics, and physicians that perform image-guided tumor ablation procedures. Its near-term commercial focus includes breast cancer treatment use cases, especially patients for whom a minimally invasive alternative to surgery is clinically appropriate.
Buy ProSense® systems and related support for use in oncology and breast care programs.
Purchase systems to offer minimally invasive cryoablation in ambulatory settings.
Influence adoption by selecting cryoablation for eligible patients and performing procedures.
Use the technology for low-risk breast cancer treatment pathways and patient management.
Strategia
IceCure’s strategy centers on expanding commercialization of ProSense® through regulatory clearances, physician adoption, and clinical evidence. The company is building installed base in the United States while using studies and conference presence to support broader market acceptance in breast cancer cryoablation.
More installed systems support recurring procedure adoption and market visibility.
Clinical evidence and guideline support help physicians adopt a new treatment modality.
Approvals in multiple territories create a path for geographic diversification.
Maantiede
2025IceCure is headquartered in Caesarea, Israel, and operates through subsidiaries in the United States, Hong Kong, and China. Its products have received regulatory approvals for marketing in the United States, Europe, and other territories, and the U.S. market is an important commercialization area for ProSense®.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
IceCure faces the typical risks of an early commercial medical device company: adoption can be slow, reimbursement and physician practice patterns may limit procedure volumes, and additional funding may be needed to support development and commercialization. Regulatory execution, competitive alternatives, and dependence on continued clinical evidence generation are also material because the business model relies on converting approvals into routine clinical use.
- Need for additional financingVaikutus: KorkeaTodennäköisyys: Korkea
The company has accumulated losses and negative operating cash flow, and future commercialization depends on outside funding.
Kohdistuu - Slow adoption of a new procedureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Cryoablation must win physician trust, workflow acceptance, and clinical preference versus established surgical options.
Kohdistuu: U.S. breast cancer commercialization
- Regulatory and indication riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Sales depend on maintaining approvals and extending use across territories and patient groups.
Kohdistuu - Competition from alternative therapiesVaikutus: KeskitasoTodennäköisyys: Korkea
Patients and physicians may choose surgery or other ablation technologies instead of cryoablation.
Kohdistuu: Tumor treatment market
Kirjanpito
Harkinnanvaraiset erätDevice sales and related service obligations may affect when revenue is recorded.
Vaikutus: Can shift reported revenue between periods
Accumulated losses and operating cash burn require management to assess funding assumptions.
Vaikutus: Affects disclosure and valuation of the business
Financing-related instruments may require fair-value measurement and remeasurement.
Vaikutus: Can create non-cash gains or losses
Right-of-use assets and lease liabilities are recognized for facilities and equipment.
Vaikutus: Affects balance sheet leverage and operating expense presentation
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Intercure Ltd.
INCR · Pharmaceutical Preparations
AtriCure, Inc.
ATRC · Surgical & Medical Instruments & Apparatus
AtriCure designs and sells surgical devices used by cardiac surgeons and electrophysiologists to treat atrial fibrillation, manage the left atrial appendage, and reduce post-operative pain.
NovoCure Ltd
NVCR · Surgical & Medical Instruments & Apparatus
NovoCure Ltd develops and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment delivered through portable medical devices and arrays worn by patients.
NextCure, Inc.
NXTC · Pharmaceutical Preparations
Baird Medical Investment Holdings Ltd
BDMDW · Surgical & Medical Instruments & Apparatus
Baird Medical Investment Holdings Ltd is a U.S.-listed medical device company focused on minimally invasive ablation technologies for solid tumors.
Pulse Biosciences, Inc
PLSE · Surgical & Medical Instruments & Apparatus
Pulse Biosciences is a U.S.-based medical technology company focused on developing and commercializing nonthermal pulsed field ablation systems.
Päivitetty: 28.9.2026